Poolbeg Pharma PLC (POLB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Poolbeg Pharma PLC (POLB) has a cash flow conversion efficiency ratio of -0.251x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-2.16 Million ≈ $-263.05 USD) by net assets (GBX8.60 Million ≈ $1.05K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Poolbeg Pharma PLC balance sheet quality to measure how much of total assets are equity-financed.
Poolbeg Pharma PLC - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Poolbeg Pharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Poolbeg Pharma PLC (POLB) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Poolbeg Pharma PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Poolbeg Pharma PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cobra Resources PLC
LSE:COBR
|
-0.060x |
|
Staffline Group Plc
LSE:STAF
|
0.275x |
|
J Smart Co Contractors PLC
LSE:SMJ
|
0.039x |
|
Sacks Parente Golf, Inc. Common Stock
NASDAQ:SPGC
|
-0.252x |
|
Galileo Tech Ltd
TA:GLTC
|
0.023x |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
3.264x |
|
Chariot Oil & Gas Limited
LSE:CHAR
|
-0.033x |
|
Oxford Metrics plc
LSE:OMG
|
0.069x |
Annual Cash Flow Conversion Efficiency for Poolbeg Pharma PLC (2021–2025)
The table below shows the annual cash flow conversion efficiency of Poolbeg Pharma PLC from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see POLB market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX8.60 Million ≈ $1.05K |
GBX-4.51 Million ≈ $-548.49 |
-0.524x | -4.61% |
| 2024-12-31 | GBX9.27 Million ≈ $1.13K |
GBX-4.65 Million ≈ $-565.28 |
-0.501x | -65.16% |
| 2023-12-31 | GBX14.44 Million ≈ $1.76K |
GBX-4.38 Million ≈ $-533.04 |
-0.303x | -27.25% |
| 2022-12-31 | GBX18.32 Million ≈ $2.23K |
GBX-4.37 Million ≈ $-531.46 |
-0.238x | -150.83% |
| 2021-12-31 | GBX22.58 Million ≈ $2.75K |
GBX-2.15 Million ≈ $-261.11 |
-0.095x | -- |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more